Cite
HARVARD Citation
Teeple, A. et al. (2022). Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis. Journal of dermatological treatment. pp. 518-524. [Online].